Pulmonary Embolism Market Set to Reach $3.63 Billion by 2029 with 12.5% Yearly Growth

Which drivers are expected to have the greatest impact on the over the pulmonary embolism market's growth?
The escalating incidence of blood clots is projected to surge the expansion of the pulmonary embolism market in the future. Blood clots, also referred to as thrombi, are gel-like or semisolid masses that develop within a blood vessel, heightening the risk of pulmonary embolism by disrupting blood flow to the lungs. Blood clots typically cause obstructions in the deep veins of the legs, thereby escalating pulmonary embolism risk. For example, in April 2022, an article by Gavi, the Vaccine Alliance, a global organization aimed at enhancing access to underutilized and new vaccines for children, mentioned that researchers identified a 33-fold surge in potential fatal lung clot risks and a five-fold increase in the likelihood of deep vein thrombosis, following a 30-day exposure to COVID-19. Therefore, the escalating incidence of blood clots is pushing forward the expansion of the pulmonary embolism market.

Rising incidences of cancer are projected to surge the growth of the pulmonary embolism market. Cancer is defined by a collection of diseases characterized by the unsuppressed and abnormal cell growth in the body, and its increasing prevalence heightens the probability of blood clot development, such as pulmonary embolism, in people afflicted with the disease. This surge creates a higher demand for treatment and diagnostics, including specialized drugs. For example, in January 2024, the American Cancer Society, a US-based nonprofit cancer advocacy organization, recorded an increase in cancer cases to 2,001,140 compared to 1,958,310 in 2023, indicating a 2.19% growth. Consequently, this rising prevalence of cancer is fueling the expansion of the pulmonary embolism market.

Get Your Pulmonary Embolism Market Report Here:
https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

What is the future CAGR of the pulmonary embolism market, and how will it impact industry expansion?
In recent times, the market size of pulmonary embolism has experienced a swift expansion. The growth is expected to increase from $2.03 billion in 2024 to $2.27 billion in 2025, with a compound annual growth rate (CAGR) of 11.9%. The historical period growth is attributed to factors such as anticoagulant therapies, ongoing research and clinical trials, increased awareness about pulmonary embolism, and vte prophylaxis.

In the coming years, the size of the pulmonary embolism market is predicted to experience swift expansion. Its valuation is predicted to reach $3.63 billion by the year 2029, increasing at a compound annual growth rate (CAGR) of 12.5%. The growth anticipated within this forecasted period is set to be driven factors such as targeted therapies, telemedicine along with remote monitoring, health equity initiatives and worldwide health initiatives. The forecasted period is also expected to witness major trends such as the adoption of artificial intelligence in diagnoses, the introduction of innovative anticoagulants, the organization of pulmonary embolism response teams, and the emphasis on patient-centered care.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp

What are the most significant trends transforming the pulmonary embolism market today?
In the market for pulmonary embolism, key players are concentrating on the development of groundbreaking products, among them the Triever16 Curve catheter and the RevCore thrombectomy catheter, as a strategy for securing competitive advantage. In correspondence with this, Inari Medical Inc., an American medical technology firm, initiated the launch of the Triever16 Curve catheter and the RevCore thrombectomy catheter in June 2023. The innovative Triever16 Curve catheter, specifically designed for peripheral thrombectomy and pulmonary embolism procedures, boasts high trackability and a pre-existing curve for targeted aspiration. Moreover, its unique construction enables straightforward access to larger and more potent 20F or 24F catheters, while the RevCore thrombectomy catheter is engineered to manage venous in-stent thrombosis. Utilizing a nitinol basket, this mechanical thrombectomy device performs the maneuver of capturing and eradicating blood clots. Furthermore, these catheters augment the safety and efficacy of pulmonary embolism procedures.

Which key market segments comprise the pulmonary embolism market and drive its revenue growth?
The pulmonary embolism market covered in this report is segmented -

1) By Treatment: Medications, Mechanical Devices, Other Treatments
2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis
3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Medications: Anticoagulants, Thrombolytics
2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy
3) By Other Treatments: Surgical Embolectomy, Supportive Care

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13026

Which geographical regions are pioneering growth in the pulmonary embolism market?
North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the leading players fueling growth in the pulmonary embolism market?
Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13026&type=smp

What Is Covered In The Pulmonary Embolism Global Market Report?

•Market Size Forecast: Examine the pulmonary embolism market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the pulmonary embolism market for a structured understanding.
•Key Players Overview: Analyze major players in the pulmonary embolism market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the pulmonary embolism market.
•Segment Contributions: Evaluate how different segments drive overall growth in the pulmonary embolism market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the pulmonary embolism market.
•Industry Challenges: Identify potential risks and obstacles affecting the pulmonary embolism market.
•Competitive Landscape: Review strategic developments in the pulmonary embolism market, including expansions, agreements, and new product launches.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.